Drug interactions
Bicalutamide + Zanubrutinib
Severity: Minor
Bicalutamide and Zanubrutinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Zanubrutinib is metabolized mainly by CYP3A4, and inhibitors increase exposure, raising risks of bleeding, cytopenias and arrhythmia. Bicalutamide is a weak inhibitor, so a labeled dose reduction is probably not required.
What this interaction means in plain words
Bicalutamide and Zanubrutinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Bicalutamide belongs to Endocrine; Zanubrutinib belongs to Oncology.
Why it happens
Possible weak inhibition of CYP3A4-mediated zanubrutinib metabolism by bicalutamide.
What to do
Monitor blood counts and for bleeding; reduce zanubrutinib to 80 mg twice daily only if a true moderate inhibitor effect is judged to be present.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bicalutamide and Zanubrutinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Bicalutamide
- Bicalutamide + Lomitapide Major
- Aminolevulinic acid + Bicalutamide Moderate
- Bicalutamide + Eliglustat Moderate
- Bicalutamide + Flibanserin Moderate
- Bicalutamide + Ivosidenib Moderate
- Bicalutamide + Lonafarnib Moderate
Other interactions of Zanubrutinib
Frequently asked questions
Can I take Bicalutamide with Zanubrutinib?
MediHelp rates the interaction as minor. Bicalutamide and Zanubrutinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Zanubrutinib is metabolized mainly by CYP3A4, and inhibitors increase exposure, raising risks of bleeding, cytopenias and arrhythmia. Bicalutamide is a weak inhibitor, so a labeled dose reduction is probably not required.
How serious is the interaction between Bicalutamide and Zanubrutinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and for bleeding; reduce zanubrutinib to 80 mg twice daily only if a true moderate inhibitor effect is judged to be present.
What other medicines interact with Bicalutamide?
MediHelp also lists interactions of Bicalutamide with, for example, Lomitapide, Aminolevulinic acid, Eliglustat. The full list is on the Bicalutamide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
